Amplia has announced that recruitment of the final cohort of patients in the ACCENT clinical trial has begun with the first patient having started on trial this week.
A total of 50 patients are planned for the Phase 2a ACCENT trial. Recruitment of this final cohort of 24 patients is open at the existing trial sites in Australia and South Korea, including the Calvary Mater Hospital in Newcastle that became an active trial site this week. Recruitment is expected to be completed by end of Q1 2025.
Amplia CEO and MD Dr Chris Burns commented:
“We are very pleased to begin recruitment of the remaining 24 patients for the ACCENT trial. We plan to complete recruitment by the end of March 2025, and to increase the opportunities for patients to join the trial we have this week also opened recruitment at the Calvary Mater Hospital in Newcastle."
Click to read the ASX release.
